Dr Edwin Jabbari details
Telephone:
Email:
Location:
- National Hospital for Neurology and Neurosurgery
GMC/GDC number:
7169723
Professional background
Dr Edwin Jabbari is a consultant neurologist working at the National Hospital for Neurology and Neurosurgery (NHNN) with clinical and research expertise in movement disorders. He runs a weekly specialist movement disorders clinic at NHNN, where he has a particular interest in Parkinson’s disease (PD), Parkinson-plus disorders (including progressive supranuclear palsy (PSP), corticobasal syndrome and multiple system atrophy), and young-onset/inherited movement disorders. He also has an interest in acute neurology and sees neurological referrals at University College London Hospitals.
Dr Jabbari completed his medical degree at University College London (UCL) Medical School with pre-clinical and clinical distinctions. He conducted his general medical training across various London hospitals before undertaking a PhD in clinical neurosciences at UCL. He then completed his neurology training at the Royal Free Hospital and NHNN. He was appointed as a consultant neurologist and research group leader after being awarded a prestigious Clinician Scientist Fellowship from the UK Medical Research Council.
Specialties
Research interests
Dr Jabbari is an internationally established research group leader at the UCL Queen Square Institute of Neurology. His work in PD and PSP focuses on: a) developing tests to enhance the speed and accuracy of diagnosis; b) discovering novel treatment targets; c) leading clinical trials.
His research has contributed to over 50 peer-reviewed publications, including publications in Lancet Neurology, JAMA Neurology and Nature Medicine. He has been awarded national and international prizes, including the Queen Square Prize in Neurology (2020) and the Junior Award by the International Parkinson and Movement Disorder Society (2024). He serves on various committees of the Michael J Fox Foundation and the International Parkinson and Movement Disorder Society.
Publications
SELECTED 1st AUTHOR PUBLICATIONS
Jabbari E and Duff KE. Tau-targeting antibody therapies: too late, wrong epitope or wrong target? Nature Medicine 2021; 27: 1341-1342.
Jabbari E, Koga S, Valentino R, et al. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology 2021; 20: 107-116.
Jabbari E, Chelban V, Holland N, et al. Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurology 2020; 77: 377-387.
Jabbari E, Woodside J, Tan MMX, et al. The genetic and clinico-pathological profile of early onset progressive supranuclear palsy. Mov Disorders 2019; 34: 1307-1314.
Jabbari E, Woodside J, Guo T, et al. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. JNNP. 2019; 90:1-7.
Jabbari E, Woodside J, Tan MMX, et al. Variation at the TRIM11 locus modifies Progressive Supranuclear Palsy phenotype. Ann Neurol. 2018; 84:485-496.
SENIOR AUTHOR PUBLICATIONS
Orru CD, Vaughan DP, Vijiaratnam V, et al. Diagnostic and prognostic value of alpha-synuclein seed amplification assay kinetic measures in Parkinson’s disease: a longitudinal cohort study. Lancet Neurology 2025: 24: 580-590.
Vaughan DP, Fumi R, Theilmann Jensen M, et al. Evaluation of cerebrospinal fluid a-synuclein seed amplification assay in progressive supranuclear palsy and corticobasal syndrome. Mov Disorders 2024; 39: 2285-2291.